Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
Intervalo de año de publicación
1.
Ceska Slov Farm ; 72(4): 172-183, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37805263

RESUMEN

Neuroinflammation plays an important role in the pathogenesis of epilepsy, so it is necessary to clarify the influence of standard antiepileptic drugs as well as adjuvant agents (e.g., cardiac glycoside digoxin, which previously showed a clear anticonvulsant potential) on cyclooxygenase pathway and neuron-specific enolase under the conditions of chronic epileptogenesis. The aim of the article is to determine the effect of digoxin, sodium valproate, and celecoxib per se, as well as the combination of digoxin with sodium valproate on the content of cyclooxygenase 1 and 2 types, prostaglandins E2, F2α, I2, thromboxane B2, 8-isoprostane and neuron-specific enolase in the brain of mice in the pentylenetetrazole-induced kindling model. It was found that only the combination of sodium valproate with digoxin provides a complete protective effect (absence of seizures) and shows the clearest influence on neuroinflammation markers and neuronal damage than monotherapy with each of these drugs and celecoxib, which appeared to be an ineffective anticonvulsant. The obtained results indicate that digoxin is a promising adjuvant drug to classical antiepileptic drugs (mostly sodium valproate) in epilepsy treatment.c.


Asunto(s)
Epilepsia , Ácido Valproico , Ratas , Ratones , Animales , Ácido Valproico/farmacología , Ácido Valproico/uso terapéutico , Anticonvulsivantes/farmacología , Anticonvulsivantes/uso terapéutico , Pentilenotetrazol/farmacología , Pentilenotetrazol/uso terapéutico , Celecoxib/farmacología , Celecoxib/uso terapéutico , Prostaglandina-Endoperóxido Sintasas/uso terapéutico , Digoxina/uso terapéutico , Enfermedades Neuroinflamatorias , Ratas Wistar , Epilepsia/inducido químicamente , Epilepsia/tratamiento farmacológico , Fosfopiruvato Hidratasa/uso terapéutico
2.
Ceska Slov Farm ; 71(2): 78-88, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35728972

RESUMEN

The prevalence of epilepsy in the world population together with a high percentage of patients resistant to existing antiepileptic drugs (AEDs) stimulates the constant search for new approaches to the treatment of the disease. Previously a significant anticonvulsant potential of cardiac glycoside digoxin has been verified by enhancing a weak activity of AEDs in low doses under screening models of seizures induced by pentylenetetrazole and maximal electroshock. The aim of the present study is to investigate the influence of digoxin at a sub-cardiotonic dose on the anticonvulsant activity of valproate, levetiracetam, and topiramate in models of primary generalized seizures with different neurochemical mechanisms. A total of 264 random-bred male albino mice have been used. AEDs were administered 30 min before seizure induction once intragastrically at conditionally effective (ED50) and sub-effective (½ ED50) doses: sodium valproate and topiramate - at doses of 300 and 150 mg/kg; levetiracetam - at doses of 100 and 50 mg/kg. Digoxin was administered once subcutaneously at a dose of 0.8 mg/kg body weight (1/10 LD50) 10-15 min before seizure induction. Picrotoxin (aqueous solution 2.5 mg/kg, subcutaneously), thiosemicarbazide (aqueous solution 25 mg/kg, intraperitoneally), strychnine (aqueous solution 1.2 mg/kg, subcutaneously), camphor (oil solution 1000 mg/kg, intraperitoneally) have been used as convulsive agents for seizure induction. It was found that under the conditions of primary generalized seizures induced by picrotoxin, thiosemicarbazide, strychnine, and camphor, digoxin not only shows its own strong anticonvulsant activity but also significantly enhances the anticonvulsant potential of classical AEDs sodium valproate, levetiracetam, and topiramate. The obtained results substantiate the expediency of further in-depth study of digoxin as an anticonvulsant drug, in particular, the in-depth study of neurochemical mechanisms of its action.


Asunto(s)
Anticonvulsivantes , Digoxina , Levetiracetam , Convulsiones , Topiramato , Ácido Valproico , Animales , Anticonvulsivantes/uso terapéutico , Alcanfor/uso terapéutico , Cardiotónicos/uso terapéutico , Digoxina/uso terapéutico , Levetiracetam/uso terapéutico , Masculino , Ratones , Picrotoxina , Convulsiones/inducido químicamente , Convulsiones/tratamiento farmacológico , Convulsiones/prevención & control , Estricnina , Topiramato/uso terapéutico , Ácido Valproico/uso terapéutico
3.
Epilepsy Res ; 167: 106465, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-33010621

RESUMEN

The worldwide prevalence of epilepsy with high percentage of multidrug-resistant patients make it urgent to find new approaches to treating, including the use of combinations of classic anticonvulsants with drugs that have an exclusively original mechanism of action, in particular digoxin. The aim of this work was to investigate the influence of low-dose digoxin on the anticonvulsant effect of sodium valproate, topiramate, levetiracetam, phenobarbital and clonazepam. A basic model of pentylenetetrazole-induced seizures in mice was used. Antiepileptic drugs were administered intragastrically in conditionally effective (ED50) and sub-effective (½ ED50) doses at 30 min, digoxin - subcutaneously at a dose of 0.8 mg/kg (1/10 LD50) at 10-15 min before seizures induction. Pentylenetetrazole at a dose of 80 mg/kg was administered subcutaneously. Experimental data demonstrates that cardiac glycoside digoxin enhances the anticonvulsant activity of sodium valproate, topiramate, levetiracetam, phenobarbital and clonazepam in the model of pentylenetetrazole-induced seizures, providing a clear protective effect of their sub-effective doses. Digoxin may be a valuable component of adjuvant pharmacotherapy for epilepsy, as it reduces the doses of the classic AEDs without compromising the effectiveness of treatment.


Asunto(s)
Anticonvulsivantes/farmacología , Digoxina/farmacología , Epilepsia/tratamiento farmacológico , Convulsiones/tratamiento farmacológico , Animales , Digoxina/efectos adversos , Levetiracetam/uso terapéutico , Masculino , Ratones , Fenobarbital/farmacología , Convulsiones/inducido químicamente , Ácido Valproico/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA